Clinical trial

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

NCT05573126

Drugs and interventions used in this trial

6 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention EP0062 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Elacestrant Normalized identity: elacestrantView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Everolimus Normalized identity: everolimusView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Abemaciclib Normalized identity: abemaciclibView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Fulvestrant Normalized identity: fulvestrantView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Exemestane Normalized identity: exemestaneView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE1, PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2023-01-11

PhasePHASE1 / PHASE2

Conditions

Hormone Receptor-positive Breast Cancerverified · MONDO: hormone receptor-positive breast cancer

Hormone Receptor Positive HER-2 Negative Breast Cancerunresolved

Metastatic Breast Cancerunresolved

Interventions

EP0062DRUG

ElacestrantDRUG · verified · RxNorm: elacestrant

EverolimusDRUG · verified · RxNorm: everolimus

AbemaciclibDRUG · verified · RxNorm: abemaciclib

FulvestrantDRUG · verified · RxNorm: fulvestrant

ExemestaneDRUG · verified · RxNorm: exemestane

Sponsors & collaborators

Ellipses Pharmalead sponsor

Mapped research locations

MadridSpain2 BostonMassachusetts, United States1 DallasTexas, United States1 NashvilleTennessee, United States1 BarcelonaSpain1 TampaFlorida, United States1 DetroitMichigan, United States1 New HavenConnecticut, United States1 FairfaxVirginia, United States1 LiverpoolUnited Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05573126 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.